Characteristics of responders
Patient . | Age, y/sex . | Diagnosis . | Salvage . | CRD1; CRD2; CRD3, mo . | Prior therapy . | Karyotype . | Response/duration in months . |
|---|---|---|---|---|---|---|---|
| 1 | 63/M | AML | 2 | 3.5;5 | Thalidomide × 2 | Deletion 5q− | CR/7.5+ |
| 2 | 61/M | AML | 1 | 10.5 | CAT + ATRA | Diploid | CR/5 |
| 3 | 73/F | AML | 1 | 13.5 | IA | Diploid | CR/2 |
| 4 | 53/M | AML | 1 | 0 | FA + mylotarg | Multiple | CR/4 |
| 5 | 32/F | AML | 1 | 29 | CAT + GCSF | Diploid | CR/10.5+ |
| 6 | 65/M | AML | 1 | 32 | CAT + GCSF | t(10;11) (p13;q21) | CR/5.5 |
| 7 | 75/F | AML | 3 | 0; 5; 9 | CAT; mylotarg; clofarabine | Diploid | CR/5.5 |
| 8 | 60/M | AML | 1 | 16 | IA | Diploid | CR/8+ |
| 9 | 22/M | AML | 1 | 30 | IA | Diploid | CR/11+ |
| 10 | 58/M | AML | 2 | 18; 18 | CAT + GCSF troxatyl + topotecan | Diploid | CR/4 |
| 11 | 46/M | AML | 2 | 24; 22 | IA; FAM; MUD SCT in CR | t(11;19) + other | CR/3.5+ |
| 12 | 74/M | AML | 2 | 11; 0 | IA; gelonin | t(9;11), deletion 7q−, trisomy 8 | CR/7 |
| 13 | 58/M | AML | 1 | 32.5 | IA | Trisomy 8 + other | CR/2.5+ |
| 14 | 34/M | CML-BP | 1 | 7 | imatinib* | Ph + other | CR/7 (died in CR) |
| 15 | 46/M | CML-BP | 1 | NA | IFN + LDAC*; imatinib | Double Ph, trisomy 8, isochromosome 17 | CR/3 (died in CR) |
| 16 | 67/M | CML-BP | 2 | 3 | HCVAD + imatinib | Ph | CR/7 |
| 17 | 46/M | CML-BP | 1 | NA | None | Ph | CR/6+ |
| 18 | 61/F | MDS | 1 | First Rx for MDS | COAP†; IFN + LDAC; 9NC | Diploid | CR/5+ |
| 19 | 70/M | MDS | 1 | 12 | IA | t(5; 12) | CR/2 |
| 20 | 61/F | AML | 2 | 8;7 | IA;mylotarg + ara-C | t(8;21) | CRp/3.5 |
| 21 | 57/F | AML | 2 | 27;30 | CAT + ATRA; lipo DNR + HDAC | t(3;21) + other | CRp/2 |
| 22 | 28/F | AML | 2 | 12; 6.5 | IA; HDAC; MUD in CR | Diploid | CRp/4.5 |
| 23 | 76/M | AML | 1 | 20.5 | IA | Trisomy 8; 20q- | CRp/1 |
| 24 | 39/M | CML-BP | 2 | 0 | IFN + hydrea*; allo SCT; IA + imatinib | Ph; trisomy 8 | CRp/5 |
| 25 | 37/F | CML-BP | 1 | NA | PEG IFN + LDAC*; imatinib; Lonafarnib | Ph + other | CRp/5 |
| 26 | 60/F | MDS | 2 | 0 | DNR + HDAC; mylotarg | Chromosome 5 and 7 abnormalities | CRp/1.3 |
| 27 | 82/F | MDS | 1 | 9 | IA | Chromosome 5 and 7 abnormalities | CRp/2 |
| 28 | 31/M | ALL | 1 | 0 | VAD | Ph, monosomy 7 | CR/4 |
| 29 | 23/M | ALL | 3 | 20.5; 3; 0 | CALGB ALL therapy; allo SCT; IA;, asparaginase + VP | Multiple | CRp/1 |
| 30 | 42/M | CML-BP | 2 | 14 | imatinib | Ph | PR/1 |
Patient . | Age, y/sex . | Diagnosis . | Salvage . | CRD1; CRD2; CRD3, mo . | Prior therapy . | Karyotype . | Response/duration in months . |
|---|---|---|---|---|---|---|---|
| 1 | 63/M | AML | 2 | 3.5;5 | Thalidomide × 2 | Deletion 5q− | CR/7.5+ |
| 2 | 61/M | AML | 1 | 10.5 | CAT + ATRA | Diploid | CR/5 |
| 3 | 73/F | AML | 1 | 13.5 | IA | Diploid | CR/2 |
| 4 | 53/M | AML | 1 | 0 | FA + mylotarg | Multiple | CR/4 |
| 5 | 32/F | AML | 1 | 29 | CAT + GCSF | Diploid | CR/10.5+ |
| 6 | 65/M | AML | 1 | 32 | CAT + GCSF | t(10;11) (p13;q21) | CR/5.5 |
| 7 | 75/F | AML | 3 | 0; 5; 9 | CAT; mylotarg; clofarabine | Diploid | CR/5.5 |
| 8 | 60/M | AML | 1 | 16 | IA | Diploid | CR/8+ |
| 9 | 22/M | AML | 1 | 30 | IA | Diploid | CR/11+ |
| 10 | 58/M | AML | 2 | 18; 18 | CAT + GCSF troxatyl + topotecan | Diploid | CR/4 |
| 11 | 46/M | AML | 2 | 24; 22 | IA; FAM; MUD SCT in CR | t(11;19) + other | CR/3.5+ |
| 12 | 74/M | AML | 2 | 11; 0 | IA; gelonin | t(9;11), deletion 7q−, trisomy 8 | CR/7 |
| 13 | 58/M | AML | 1 | 32.5 | IA | Trisomy 8 + other | CR/2.5+ |
| 14 | 34/M | CML-BP | 1 | 7 | imatinib* | Ph + other | CR/7 (died in CR) |
| 15 | 46/M | CML-BP | 1 | NA | IFN + LDAC*; imatinib | Double Ph, trisomy 8, isochromosome 17 | CR/3 (died in CR) |
| 16 | 67/M | CML-BP | 2 | 3 | HCVAD + imatinib | Ph | CR/7 |
| 17 | 46/M | CML-BP | 1 | NA | None | Ph | CR/6+ |
| 18 | 61/F | MDS | 1 | First Rx for MDS | COAP†; IFN + LDAC; 9NC | Diploid | CR/5+ |
| 19 | 70/M | MDS | 1 | 12 | IA | t(5; 12) | CR/2 |
| 20 | 61/F | AML | 2 | 8;7 | IA;mylotarg + ara-C | t(8;21) | CRp/3.5 |
| 21 | 57/F | AML | 2 | 27;30 | CAT + ATRA; lipo DNR + HDAC | t(3;21) + other | CRp/2 |
| 22 | 28/F | AML | 2 | 12; 6.5 | IA; HDAC; MUD in CR | Diploid | CRp/4.5 |
| 23 | 76/M | AML | 1 | 20.5 | IA | Trisomy 8; 20q- | CRp/1 |
| 24 | 39/M | CML-BP | 2 | 0 | IFN + hydrea*; allo SCT; IA + imatinib | Ph; trisomy 8 | CRp/5 |
| 25 | 37/F | CML-BP | 1 | NA | PEG IFN + LDAC*; imatinib; Lonafarnib | Ph + other | CRp/5 |
| 26 | 60/F | MDS | 2 | 0 | DNR + HDAC; mylotarg | Chromosome 5 and 7 abnormalities | CRp/1.3 |
| 27 | 82/F | MDS | 1 | 9 | IA | Chromosome 5 and 7 abnormalities | CRp/2 |
| 28 | 31/M | ALL | 1 | 0 | VAD | Ph, monosomy 7 | CR/4 |
| 29 | 23/M | ALL | 3 | 20.5; 3; 0 | CALGB ALL therapy; allo SCT; IA;, asparaginase + VP | Multiple | CRp/1 |
| 30 | 42/M | CML-BP | 2 | 14 | imatinib | Ph | PR/1 |
M indicates male; F, female; AML, acute myeloid leukemia; CML-BP, chronic myeloid leukemia in blastic phase; MDS, myelodysplastic syndrome; ALL, acute lymphoid leukemia; CRD1, duration of first complete response; CAT, cyclophosphamide, ara-C, topotecan; ATRA, all transretinoic acid; IA, idarubicin + high-dose ara-C; BID FA, fludarabine + ara-C; GCSF, granulocyte colony-stimulating factor; FAM, fludarabine, ara-C, mitoxantrone; MUD SCT, matched unrelated donor stem cell transplantation; IFN, interferon alpha; LD AC, low-dose ara-C; HCVAD, hyperfractionated cyclophosphamide, vincristine, adriamycin, dexamethasone; allo SCT, allogeneic stem cell transplantation; DNR, daunorubicin; and VP, vincristine + prednisone.
Therapy for chronic phase CML.
Prior history of Ph− CML.